<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/258529-dietary-supplement-composition-for-blood-lipid-health by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 05:16:58 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 258529:&quot;DIETARY SUPPLEMENT COMPOSITION FOR BLOOD LIPID HEALTH&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;DIETARY SUPPLEMENT COMPOSITION FOR BLOOD LIPID HEALTH&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>ABSTRACT &quot;Dietary Supplement Composition for Blood Lipid Health&quot; A human or animal dietary supplement composition comprising one or more long chain (C24-C36) primary alcohols (policosanols) dispersed in food-grade oils or fats where the policosanol particle size is substantially less than ten (10) microns. The composition (Nanocosanol™) is effective and convenient for supporting blood lipid health. 23</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Related Application<br>
tOOOl] This application is based upon prior filed<br>
copending provisional application Serial No. 60/771,003<br>
filed February 1, 2006, the entire subject matter of<br>
which is incorporated herein by reference in its<br>
entirety.<br>
Field of the Invention<br>
[0002] The present invention relates to dietary<br>
supplements, and, more particularly to the formulation<br>
of such supplements containing fatty alcohols.<br>
['•' . ^ z ^ " ^ Background of the Invention<br>
[0003] Cholesterol effects have been studied for<br>
years. Examples of research are found in the following<br>
references, the disclosures which are hereby<br>
incorporated by reference in their entirety.<br>
[0004] . Albert, CM., K Oh, W Whang, JE Manson, CU<br>
Chae, MJ Stampfer, WC Willett and FB Hu. 2005. Dietary<br>
a-linolenic acid intake and risk of sudden cardiac<br>
death and coronary heart disaese. Cir-culation 112:<br>
3232-3238.<br>
[00051 Castano, G, R Mas, M Arruzazabala et al.<br>
1999. Effects of policcosanol and pravastatin on lipid<br>
profile, platelet aggregation and endothelemia in older<br>
hyperecholesterolemic patients. Jnt J Clin Phsrm Res.<br>
4: 105.<br>
*•<br>
2 'i<br>
* •<br>
w<br>
[0006] Gershkovich, P, A Hoffman. 2005. Uptake of<br>
l i p o p h i l i c d r u g s by plasma d e r i v e d i s o l a t ed<br>
c h y l o m i c r o n s : L i n t e r a l c o r e l a t i o n with' i n t e s t i n al<br>
l y m p h a t i c b i o a v a i l a b i l i t y . Eur J Pharm Sci. 26: 394-<br>
404 .<br>
[0007] Law, MR, NJ Wald and SG Thompson. 1994. By<br>
houw much and how q u i c k l y d o e s r e d u c t i o n i n serum<br>
c h o l e s t e r o l c o n c e n t r a t i o n l o w e r r i s k of i s c h a e m i c h e a rt<br>
d i s e a s e ? BMJ" 3 0 8 : 367-372.<br>
[0008] Lusis, AJ. 2000. A t h e r o s c l e r o s i s . Nature.<br>
4 0 7 ; 233-241.<br>
[0009] Mantzioris, E . , LG C l e l a n d , RA Gibson, MA<br>
Neumann, M Demasi and MJ J a m e s . 2000. Biochmical<br>
e f f e c t s of a d i e t c o n t a i n i n g foods e n r i c h e d with n-3<br>
f a t t y a c i d s . Am J Clin Nutr 72: 4 2 - 4 8.<br>
[OOIO] Mas R. 2000. P o l i c o s a n o l . Drugs Future- 25:<br>
5 6 9 - 5 8 6 .<br>
[0011] Oh, SY, J Ryeu, C H s i e h and DE B e l l . 1991.<br>
Eggs e n r i c h e d i n o-3 f a t t y a c i d s and a l t e r a t i o n s in<br>
l i p i d c o n c e n t r a t i o n s i n p l a s m a and l i p o p r o t e i n s and in<br>
b l o o d p r e s s u r e . Am J Clin Nutr. 54: 6 8 9 - 6 9 5.<br>
[0012] Rang, HP, MM D a l e and JM R i t t e r . 1999.<br>
Pharmacology. 4*^*' ed. C h u r c h i l l L i v i n g s t o n e , London.<br>
8 3 0 .<br>
[0013] Simopoulos, AP. 1 9 9 9 . E s s e n t i a l f a t t y a c i ds<br>
i n h e a l t h and c h r o n i c d i s e s a s e . Am J Clin Nutr<br>
7 0 ( s u p p l ) : 560S-9S.<br>
[0014] Taylor, JC, L R a p p o r t and GB Lockwood. 2003.<br>
O c t a c o s a n o l i n humeui h e a l t h . N u t r i t i o n . 19: 192-195.<br>
[0015] Zhao, G, TD E t h e r t o n , KR M a r t i n , SG West, PJ<br>
G i l l e s and PM K r i s - E t h e r t o n . 2004. D i e t a r y a - l i n o l e n ic<br>
a c i d reduces inflammatory a n d l i p i d c a r d i o v a s c u l a r r i s k .<br>
f a c t o r s in h y p e r c h o l e s t e r o l e m i c men and women. J Nutr<br>
1 3 4 : 2991-2997.<br>
3 -<br>
•i . .<br>
[0016] Cholesterol i s an essential component in the<br>
body and used in cell membranes. Excessive l e v e l s,<br>
however, can lead to hypercholesterolemia and<br>
a t h e r o s c l e r o s i s , which can result in coronary heart<br>
disease. Cholesterol i s transported v i a : high-, low-,<br>
intermediate-, and very low-density lipoproteins,-<br>
i<br>
chylomicron remants; and chylomicrons. High levels of<br>
J<br>
high-density lipoproteins are desirable because they i<br>
transport cholesterol from the peripheral tissues to<br>
the liver, thereby maintaining cholesterol homeostasis.<br>
The main transport mechanism, however, is low-density<br>
lipoprotein, which moves cholesterol in the blodd<br>
plasma and incorporates it into cell membranes.<br>
Increased levels of low-density lipoprotein, however,<br>
can interfere with uptake binding mechanisms.<br>
[0017J Statin drugs such as atorvastatin,<br>
fluvastatin, pravastatin and simvastatin are often<br>
administered to those suffering from cholesterol<br>
issues. These drugs inhibit competitively 3-hydjroxy-3-<br>
methylglutaryl coenzyme A reductase, thereby reducing<br>
cholesterol synthesis. Side effects of statins can<br>
^ include myositis, headache, rash, angioederaa,<br>
gastrointestinal effects and altered liver functions.<br>
In addition, these drugs should not be used in patients<br>
with renal failure or in people with compromised liver<br>
function (Taylor et al. 2003).<br>
[0018] Dietary fatty acid intake can influence many<br>
health factors, but much interest has been placed on<br>
the n - 3 (omega-3) fatty acids. These essential fatty<br>
acids include a-linolenic (ALA), eicosapentaenoic (EPA)<br>
and docosahexaenoic acid (DHA) . Various studies have<br>
shown that n - 3 fatty acids are essential for normal<br>
growth and development. They may also play a critical<br>
role in the prevention and treatment of coronary heart<br>
4 - -<br>
m<br>
d i s e a s e , h y p e r t e n s i o n , d i a b e t e s and o t h e r inflammatory<br>
and autoimmune d i s o r d e r s (Siraopoulos 1999) . ALA is<br>
p r e s e n t i n c e r t a i n v e g e t a b l e o i l s ( f l a x s e e d , cranberrys<br>
e e d , c a n o l a and c h i a ) whereas EPA and DHA a r e found in<br>
f i s h , f i s h o i l and a l g a e p r o d u c t s.<br>
[0019] Between e t h n i c d i e t a r y g r o u p s i t has been<br>
shovm t h a t t h e h i g h e r r a t i o of n - 6 t o n - 3 in<br>
thrombocyte p h o s p h o l i p i d s can be a c a u s e for a h i g h er<br>
d e a t h r a t e from c a r d i o v a s c u l a r d i s e a s e . This i n c r e a s ed<br>
r a t i o a l s o r e s u l t s i n i n c r e a s e d r a t e s of type 2<br>
d i a b e t e s , of which a t h e r o s c l e r o s i s i s a major<br>
c o m p l i c a t i o n (Weber, 1991) . Achieving t a r g e t l e v e l s of<br>
n - 3 f a t t y a c i d s can be d i f f i c u l t w i t h modem western.<br>
d i e t s d e f i c i e n t in ALA, EPA and DHA, and. e x c e s s i v e in<br>
t h e n - 6 l i n o l e i c a c i d . Target t i s s u e c o n c e n t r a t i o ns<br>
f o r ALA a n d EPA can be met with c o n s u m p t i o n of ALA<br>
( M a n t z i o r i s et a l . 2000) . A p r i m a r y c a r d i o v a s c u l ar<br>
b e n e f i t from n - 3 f a t t y a c i d i n g e s t i o n can be r e d u c ed<br>
b l o o d c l o t t i n g in v e s s e l w a l l s and r e d u c e d v e n t r i c u l ar<br>
a r r h y t h m i a s , (Zhao e t a l . (2004)). Some s t u d i e s have<br>
found a d o s e - r e s p o n s e r e l a t i o n between n - 3 i n t a k e and<br>
b e n e f i c i a l e f f e c t s on c a r d i o v a s c u l a r d i s e a s e r i sk<br>
f a c t o r s . Some s t u d i e s have shown an i n v e r se<br>
r e l a t i o n s h i p between ALA i n t a k e and r i s k of sudden<br>
c a r d i a c d e a t h (Albert e t a l . (2005.)).<br>
[0020] Policosanols can be d e f i n e d a s a mibcture of<br>
l o n g c h a i n (C24-C36) a l i p h a t i c p r i m a r y a l c o h o l s , which<br>
a r e commonly d e r i v e d from sugar c a n e , r i c e bran,<br>
beeswax, wheat or sorghum. Predominant a l c o h o l s in<br>
t h i s group a r e t e t r a c o s a n o l , h e x a c o s a n o l , o c t a c o s a n ol<br>
and t r i a c o n t a n o l.<br>
[0021] Policosanols can lower c h o l e s t e r o l l e v e l s by<br>
i n h i b i t i n g c h o l e s t e r o l b i o s y n t h e s i s v i a d o w n r p g u l a t i on<br>
of 3 - h y d r o x y - 3 - m e t h y l g l u t a r y l Coenzyme A enzyme<br>
•<br>
5 -<br>
expression (Menendez e t a l . 1994, McCarty 2002) . A<br>
study by Hernandez et a l . (1992) found a reduction in<br>
serum c h o l e s t e r o l l e v e l s of subjects talcing 20 mg<br>
policosanol per day for 4 weeks. S i g n i f i c a n t decreases<br>
in LDL l e v e l s , with i n c r e a s e d l e v e l s of HDL were also<br>
noticed. Another double-blind randomized study by .<br>
Castano, e t a l . (1999) i n v e s t i g a t e d the e f f e c t s of<br>
policosanol and p r a v a s t a t i n on the l i p i d p r o f i l e 'in<br>
older hypercholesterelemic patients. Policosanol was<br>
foxind t o increase HDL l e v e l s , but was a l s o more |<br>
e f f e c t i v e than pravastatin in lowering LDL l e v e l s and i<br>
the LDL:HDL r a t i o.<br>
[00221 Policosanols can a l s o protect l i p o p r o t e i ns<br>
from peroxidation, in b o t h l i p i d and p r o t e i n moieties .<br>
(Menendez e t a l . 1999) . This can be an important<br>
e f f e c t , s i n c e LDL o x i d a t i o n i s thought t o be a<br>
necessary s t e p in the development of a t h e r o s c l e r o s i s.<br>
[0023] Policocemols may provide fewer s i d e e f f e c ts<br>
them s t a t i n s , increase HDL cholesterol l e v e l s and have<br>
a reduced c o s t (Taylor e t a l . 2003) .<br>
[0024] One issue with policosanols are poor<br>
s o l u b i l i t y , and d i f f i c u l t y with absorbtion in the gut.<br>
Human s t u d i e s with fH] -octacosouiol showed the majority<br>
(81-91%) of total r a d i o a c t i v i t y was e x c r e d t e d in the<br>
feces, and only 1.2% of t o t a l r a d i o a c t i v i t y was found<br>
in urine (Mas, 2000) .<br>
[0025] Reducing the p a r t i c l e s i z e of poorly soluble<br>
compounds such as p o l i c o s a n o l to a micron or sub-micron<br>
range, improved autjsorbtion ahd b i o a v a i l a b i l t y is<br>
desiraJjle. Dl as WO 03/103632 uses a reduced p a r t i c l6<br>
s i z e f o r . p o l i c o s a n ol that ±« l e s s than 2,000<br>
nanometers, i . e . , 2 microns. The i n c r e a s e d surface<br>
area of the smaller nanoparticulate p a r t i c l e s requires<br>
the use of a surface s t a b i l i z e r . It i s p o s s i b l e to<br>
a l s o use pharmaceutically acceptable c a r r i e r with the<br>
6<br>
surface stabilizer. D2 as WO 02/052955 is directed to<br>
pharmaceutical and dietary compositions and functional<br>
food stuffs useful as coadjuvants for treating and<br>
preventing an aging process amd related conditions. It<br>
is directed to a lipidic mixture rich in<br>
polyunsaturated acids and vitamins, in.combination with<br>
at least two components selected from one or more<br>
terpenes selected from monoterpenes and/or<br>
sesquiterpenes, 1-piperoylpiperidine in the pure form<br>
and/or extracts or purified fractions enriched in black<br>
pepper containing it, one or more pollcosanols and/or<br>
policosanolic acids. There is no teaching concerning<br>
the policoseuiol in a micron or sub-micron range for<br>
improved absorption in bioavailability.<br>
Sxunmary of the Invention<br>
[0026] A human or animal dietary supplement<br>
composition comprises a blood lipid health-effective<br>
\ A<br>
7<br>
amount of one or more long chain (C24-C36) primaryalcohols<br>
(policosanols) dispersed in one or more foodgrade<br>
fats or oils, wherein the particle sizes of the<br>
alcohols are substantially less than 10 microns.<br>
[0027] The particle sizes of the alcohols can be<br>
substantially greater than 0.2 microns and<br>
substantially less than 5.0 microns. The alcohols can<br>
be selected from one of at least octacosanol,<br>
triacontanol and hexacosanol. The alcohols can also be |<br>
i<br>
derived from natural sources, including rice bran,<br>
beeswax, sugar cane, sorghum or wheat.<br>
[0028] In another aspect, the food-grade fats or<br>
oils contain one of at least:<br>
(a) not less than twenty five percent (25%) by<br>
weight of polyunsaturated fatty acids;<br>
(b) not less than ten percent (10%) by weight of<br>
omega-3 fatty acids;<br>
(c) not less than two and one-half percent (2.5%)<br>
by weight of squalene; and<br>
(d) not less than eight fifty parts per million<br>
(850 ppm) by weight of tocopherols and tocotrienols in<br>
total.<br>
[0029] The food-grade fats or oils could include at<br>
least one of cranberry seed oil, amaranth seed oil,<br>
fish and raarine/algal oils, safflower oil, sunflower<br>
seed oil, soybean oil, canola oil, olive oil, linseed<br>
oil, flax oil, hemp oil, borage oil, evening primrose<br>
oil, chia oil and hibiscus oil.<br>
[0030] In yet another aspect, the policosanols<br>
include about 0.1 percent by weight of the fats or oils<br>
to about 6.0 percent by weight of the fats or oils.<br>
The policosanols could also include about 0.5% by<br>
weight of the fats or oils to about 5.0%, by weight of<br>
the fats or oils, or from about 1.0% by weight of the<br>
8<br>
r<br>
fats or o i l s to about 5.0% by weight of the fats or<br>
o i l s .<br>
[0031] The composition could be formed from<br>
b i o l o g i c a l l y active e x t r a c t s and compounds, including<br>
vitamins, minerals, antioxidants, carotenoids,<br>
tocopherols, tocotrienols, phytosterols, polyphenols,<br>
} polysaccharides and bioflavonoids..<br>
[0032] A vehicle for the composition could be an<br>
emulsion, solution, dispersion, cream, t a b l e t , capsules<br>
and powder. A vehicle for carirying the composition<br>
could be food, feed or beverage.<br>
[0033] A method aspect i s also set forth.<br>
Detailed Description of the Preferred Embodiments<br>
[0034] Different embodiments will now be described<br>
more f u l l y hereinafter with reference to the<br>
accompanying drawings, in which p r e f e r r e d embodiments<br>
are shown. Many d i f f e r e n t forms can be set forth and<br>
described embodiments should not be construed as<br>
limited to the embodiments set forth herein. Rather,<br>
these embodiments are provided so t h a t t h i s disclosure<br>
will be thorough and complete, and w i l l fully convey<br>
the scope t o those s k i l l e d in the a r t.<br>
[0035] The natural d i e t a r y supplement industry<br>
represents a $300 b i l l i o n dollar marJcetplace worldwide.<br>
Many natural botanical materials and e x t r a c t s have been<br>
used by mankind for h e a l t h purposes for thousands of<br>
years. In some parts of the world, n a t u r a l health<br>
products are preferred over chemical or pharmaceutical<br>
ones due t o reasons of r e l i g i o n , c u l t u r e, safety, cost<br>
and demonstrated efficacy.<br>
[0036] Among the b o t a n i c a l products that have a<br>
history of use in support of human blood l i p i d health<br>
are c e r t a i n f a t t y alcohols derived from botanical<br>
9<br>
waxes, for example, sugar cane wax, rice bran and other<br>
cereal waxes and bees wax. The most important of these<br>
are the long chain (C24-C36) primary alcohols,<br>
octacosanol, triacontanol and hexacosanol.<br>
[0037] Policosanols, as noted above, are known to<br>
have a number of beneficial effects on blood lipid<br>
health. These beneficial effects include lowering<br>
blood cholesterol levels, reducing Low Density<br>
Lipoproteins (LDL), increasing High Density<br>
Lipoproteins (HDL) and reducing blood triglycrerides.<br>
[0038] Some difficulties have been experienced in<br>
using policosanols to improve blood lipid health. For<br>
example, these fatty alcohols are poorly soluble in<br>
lipid carriers and completely insoliible in aqueous<br>
carriers. This greatly reduces their availability in<br>
the digestive tract. Normal digestion of fats and oils<br>
in the mammalian diet is achieved by emulsification<br>
with bile salts and phospholipids followed by direct<br>
adsorption of the resulting chylomicrons through the<br>
gut wall. Typical chylomicron sizes are 0.5 microns to<br>
2 microns.<br>
[0039] Modem emulsification technology<br>
(nanotechnology) now makes it possible to produce<br>
dispersed particle sizes in liquid carriers into the 1<br>
micron size. As noted above, many different physical<br>
emulsification techniques are available.<br>
[0040] In accordance with a non-limiting example of<br>
the present invention, one or more of these<br>
technologies is used to prepare a dietary supplement<br>
composition in which the policosanol particle sizes are<br>
substantially less than 10 micron range within an<br>
acceptable oil carrier (Nanocosanol'"') . The composition<br>
may include the use of food-grade emulsifiers, for<br>
example, polysorbates, lecithin, hydrolyzed lecithin,<br>
10<br>
mono- and di-glycerides, and acylated mono- and<br>
di-glycerides. The presence of the emulsifiers<br>
inhibits the tendency of the particles to adhere under<br>
electrostatic attractive forces. Such a composition has<br>
the advantage of increased digestability and stability<br>
on storage.<br>
[00411 In one aspect, the composition includes the<br>
selection of an oil carrier with beneficial blood lipid<br>
properties. Such fats and oils may include<br>
polyunsaturated fatty acids, omega-3 fatty acids,<br>
squalene, phytosterols, tocopherols and tocotrienols.<br>
Typical fats and oils, include, for example, fish oils,<br>
shark liver oil, cranberry seed oil, amaranth seed oil,<br>
sunflower seed oil, linseed oil, chia oil artd evening<br>
primrose seed oil.<br>
[0042] In another aspect, the composition.optimizes<br>
the balanced intake of both policosanols and the<br>
beneficial lipid carrier. By suitable selection of the<br>
ratio of the carrier oil to the policosanols, it is<br>
possible to produce the composition such that preferred<br>
intakes of both policosanols and the beneficial lipid<br>
can be conveniently administered in acceptable unit and<br>
daily doses.<br>
[00431 Such a composition as (Nanocosanol™) can be<br>
used to promote and support blood lipid health. Daily<br>
intake of such composition, in the preferred dose<br>
range, will provide the subject with the desired daily<br>
intakes of policosanols and lipid carrier, resulting in<br>
improved blood lipid profiles. This can include, for<br>
example, lower cholesterol, lower triglycerides, lower<br>
Low Density Lipoprotein (LDL) and higher High Density<br>
Lipoprotein (HDL).<br>
[0044] In accordance with one aspect of the present<br>
invention, a dietary supplement composition is<br>
11<br>
d i s c l o s e d (Nanocosanol™) i n which p o o r l y s o l u b le<br>
p o l i c o s a n o l s a r e d i s p e r s e d i n food-grade o i l s or f a t s,<br>
i n which t h e p o l i c o s a n o l p a r t i c l e s i z e s i n t he<br>
c o m p o s i t i o n a r e s u b s t a n t i a l l y l e s s than lO microns and<br>
p r e f e r a b l y in t h e range of from about 0,2 microns to<br>
a b o u t 5.0 m i c r o n s.<br>
[0045] In a c c o r d a n c e w i t h a n o t h e r a s p e c t of the<br>
p r e s e n t i n v e n t i o n , the b o d y ' s a b s o r p t i o n and<br>
u t i l i z a t i o n of t h e p o l i c o s a n o l s from t h e c o m p o s i t i o n is<br>
s u b s t a n t i a l l y enhanced as compared w i t h t h e a b s o r p t i on<br>
and u t i l i z a t i o n of p o l i c o s a n o l s a d m i n i s t e r e d i n s o l id<br>
o r t a b l e t form. The p o l i c o s a n o l d i s p e r s i o n of the<br>
c o m p o s i t i o n i s s t a b l e on s t o r a g e and d o e s n o t s e p a r a te<br>
from the l i p i d c a r r i e r.<br>
[004 6] The d i s c l o s e d l i p i d c a r r i e r u s e d i n the<br>
c o m p o s i t i o n may be s e l e c t e d from a group of o i l s and or<br>
f a t s t h a t a r e Icnown t o have b e n e f i c i a l e f f e c t s on b l o od<br>
l i p i d h e a l t h . .Such b e n e f i c i a l l i p i d s , f o r example, may<br>
c o n t a i n one o r more of p o l y u n s a t u r a t e d f a t t y a c i d s,<br>
p h y t o s t e r o l s , omega-3 f a t t y a c i d s , s q u a l e n e,<br>
t o c o p h e r o l s and t o c o t r i e n o l s.<br>
[0047] The c o n c e n t r a t i o n of p o l i c o s a n o l s of the<br>
c o m p o s i t i o n o p t i m i z e s t h e d a i l y i n t a k e of b o th<br>
p o l i c o s a n o l s and the b e n e f i c i a l l i p i d c a r r i e r . The<br>
p r e f e r r e d d a i l y i n t a k e of p o l i c o s a n o l s c a n be about<br>
2 0 - 3 0 mg p e r day for an a d u l t . The p r e f e r r e d d a i ly<br>
i n t a k e for b e n e f i c i a l l i p i d s , however, i s o f t e n as h i gh<br>
a s from about 500 mg t o 5 , 0 0 0 mg per day f o r an a d u l t.<br>
The weight of p o l i c o s a n o l s i n t h e d i s c l o s e d c o m p o s i t i on<br>
i s from about 0 . 3 percent by weight of b e n e f i c i a l l i p id<br>
t o about 5.0 p e r c e n t by w e i g h t of b e n e f i c i a l l i p i d.<br>
Such a d i s c l o s e d c o a p o s i t i o n allows t h e r a t i o of<br>
b e n e f i c i a l l i p i d t o p o l i c o s a n o l s to r a n g e from about<br>
3 3 3 : 1 t o about 2 0 : 1 . This r a t i o e n s u r e s t h a t a<br>
12<br>
p o l i c o s a n o l i n t a k e of about 25 mg p e r day i s always in<br>
combination w i t h from a b o u t 500 mg p e r day t o about<br>
5,000 mg p e r day of t h e b e n e f i c i a l l i p i d . The<br>
d i s c l o s e d c o m p o s i t i o n a l l o w s d e l i v e r y of a p r e f e r r ed<br>
d a i l y dose of both p o l i c o s a n o l s and b e n e f i c i a l l i p i d in<br>
a s i n g l e f o r m u l a t i o n.<br>
[0048] It w i l l be un4|^aigtood by t h o s e i n t h e a rt<br>
t h a t l i q u i d d i e t a r y supplement d a i l y d o s e s of from<br>
about 500 mg t o about 5,000 mg can be c o n v e n i e n t ly<br>
d e l i v e r e d i n c a p s u l e s from about 500 mg t o about 1,000<br>
mg. For example, a t h r e e p e r c e n t d i s p e r s i o n of<br>
p o l i c o s a n o l s in a b e n e f i c i a l l i p i d can c o n v e n i e n t ly<br>
supply 24 mg of p o l i c o s a n o l s per day t o g e t h e r w i t h 800<br>
rag of b e n e f i c i a l l i p i d , when taken a s two 400 mg<br>
c a p s u l e s d a i l y.<br>
[0049] It w i l l be u n d e r s t o o d by t h o s e i n t h e a rt<br>
t h a t such a c o m p o s i t i o n , in c a p s u l e o r l i q u i d form, may<br>
be c o n v e n i e n t l y supplemented with o t h e r b i o l o g i c a l ly<br>
a c t i v e e x t r a c t s and compounds, i n c l u d i n g , for example,<br>
v i t a m i n s , m i n e r a l s , a n t i o x i d a n t s , c a r o t e n o i d s,<br>
t o c o p h e r o l s , t o c o t r i e n o l s , p h y t o s t e r o l s , f a t ty<br>
a l c o h o l s , p o l y s a c c h a r i d e s and b i o f l a v o n o i d s.<br>
[0050] The d i s c l o s e d d i e t a r y supplement c o m p o s i t i on<br>
(Nanocosanol^^) i s a n o v e l , improved, more e f f i c i e nt<br>
v e h i c l e f o r • t h e a d m i n i s t r a t i o n of p o l i c o s a n o l s in<br>
support of b l o o d l i p i d h e a l t h . I t i s e f f e c t i v e in<br>
lowering t h e blood serum c h o l e s t e r o l l e v e l of b o th<br>
normal and h y p e r c h o l e s t e r o l e m i c s u b j e c t s.<br>
10051] The f o l l o w i n g examples a r e i l l u s t r a t i v e of<br>
t h e p r e s e n t i n v e n t i o n , and a r e not t o be c o n s t r u e d as<br>
l i m i t i n g t h e r e o f.<br>
13<br>
EXAMPLE 1<br>
[0052] Supercritical CO2 Extracts of Cranberry<br>
(Vacclnium macrocarpon) Seed, Amaranth {AmaxanthuS'<br>
s<br>
hypochondriacus) Seed and Rice (Oryza sativa) bran wax<br>
were individually manufactured in a commercial 150<br>
liter extraction unit. Within a heated vessel, the<br>
policosanol containing rice bran wax extract was<br>
dissolved into a mixture of cranberry and amaranth seed<br>
oily extracts at €5°C. After cooling to ambient<br>
temperature, soybean lecithin was combined. This<br>
resultant formulation was processed in a high pressure<br>
homogenization unit to obtain a stable dispersion of<br>
rice bran wax. The homogenizer is designed to produce<br>
high rates of shear and cavitation. Using light<br>
microscopy, average particle size was determined.<br>
Composition of the dispersion was as follows:<br>
Policosanols: 1.45%, average particle size 0.3 - 2.6 um.<br>
alpha-Linolenic acid: 13.2%<br>
Squalene: 3%<br>
Tocopherols: 499 pg/g<br>
Tocotrienols: 709 pg/g<br>
Phytosterols: 4.4 mg/g<br>
&gt;<br>
EXAMPLE 2<br>
[0053] The Nanocosanol f o r m u l a t i o n from Example 1<br>
was e n c a p s u l a t e d i n s t a n d a r d g e l a t i n s o f t g e l s by a<br>
t h i r d p a r t y m a n u f a c t u r e r . Softgels were 690 mg nominal<br>
f i l l weight and e a c h c o n t a i n e d 10 mg p o l i c o s a n o l , 21 mg<br>
s q u a l e n e , 91 mg n - 3 f a t t y a c i d s ( a l p h a - l i n o l e n i c ) , 3.0<br>
mg p h y t o s t e r o l s , 489 pg t o c o t r i e n o l s and 344 pg<br>
t o c o p h e r o l s ,<br>
EXAMPLE 3<br>
[0054] Nanocosanol^ s o f t g e l s , manufactured a c c o r d i n g .<br>
t o Example 2 were a d m i n i s t e r e d t o 11 s x i b j e c t s over an<br>
a p p r o x i m a t e l y 3-month p e r i o d . The s t u d y was a non-<br>
14<br>
placebo controlled open l a b e l t r i a l and used volunteers<br>
with normal and modestly elevated levels of serum<br>
cholesterol. Starting point individual cholesterol<br>
levels ranged from about 14 0 ho about 258. Dosage was<br>
2 X 600 mg capsules per day providing 20 mg per day of<br>
policosanols together with 1200 mg per day of a 50:50<br>
mixture of Cranberry and Amaranth Seed o i l s . In<br>
addition to the Policosonols, the Nanocosanol™<br>
formulation provided tocopherols, t o c o t r i e n o l s , omega-6<br>
and omega-3 f a t t y acids, polyunsaturated f a t t y acids<br>
and squalene.<br>
[0055] Subject blood samples were taken by an<br>
independent c l i n i c at 0 (Base), 30, 60 and 90 days.<br>
The blood samples were subjected to Blood Lipid by an<br>
authorized independent laboratory.<br>
[0056] Variables measured were Triglycerides,<br>
Cholesterol, LDL Cholesterol and HDL Cholesterol.<br>
[0057] All data were expressed as a difference<br>
(change) from the Base l e v e l for that subject and that<br>
variable. One subject did not complete a blood sample<br>
at 90 days so the total number of observations was 32<br>
(11, 11, 10) . Analyses were based the combined data<br>
over a l l three periods. The mean changes for the Blood<br>
Lipid v a r i a b l e s were:<br>
Triglycerides - 4.72* p= 0.175<br>
LDL Choi. - 10.06% p= 0.125<br>
HDL Choi. + X.85% p« 0.175<br>
OTHER Choi. - 5.23% p= 0.125<br>
Choi. - 5.96% p= 0.050<br>
LDL/HDL - 11.73% p= 0.050<br>
Chol/HDL - 7.43% p= 0.05O<br>
[0058] The Cholesterol reduction of 5.96% was<br>
significant at the 5% l e v e l of p r o b a b i l i t y using the<br>
One-sided t - t e s t with 31 DF, as were the LDL/HDL r a t io<br>
and the Chol/HDL r a t i o . The other Blood Lipid decreases<br>
15<br>
are not s i g n i f i c a n t at the 5% Level but have only a 1<br>
i n 6 to about 1 in 8 chance of occurring by chance.<br>
[0059] Analysis of Covariance was used t o estimate<br>
the linear regression of v a r i a b l e change on variable<br>
-Base level. Both the pooled within period regression<br>
coefficient and the overall regression c o e f f i c i e n t for<br>
most variables were negative, highly s i g n i f i c a n t at the<br>
1% level (1 and 30 DF) and v i r t u a l l y i d e n t i c a l.<br>
[0060] Using the estimated regression equation, an<br>
estimate of the varieible reduction r e s u l t i n g from a<br>
"typical high-quartile" Base level was c a l c u l a t e d for<br>
each variable. These are shown as follows:<br>
T r i g l y c e r i d e b= - 0 . 2 9 1 8 p
L.DL b= - 0 . 8 2 3 4 p
HDL b= ^ 0 . 0 8 5 4 p-0.175<br>
OTHER Choi b= - 0 . 2 8 7 0 p
Choi b=. - 0 . 7 7 0 4 pi225 Chng= - 2 4 . 2 7 (-10.78%)<br>
LDL/HDL • b= - 0 . 4 5 3 4 p
Chol/HDL b= - 0 . 3 5 7 7 p
[0061] It can be seen from the r e s u l t i n g data that<br>
the Ncuaocosanol'"* treatment resulted in s i g n i f i c a n t and<br>
near significant reductions over base l e v e l -for a ll<br>
Blood Lipid variables except HDL which showed a small<br>
increase. Nanocosamol™ was c l e a r l y and demonstrably<br>
responsible for a significant improvement in Blood<br>
Lipid health. This is most c l e a r l y e s t a b l i s h e d for<br>
Total Cholesterol and the c r i t i c a l LDL/HDL and Chol/HDL<br>
r a t i o s . It i s also l i k e l y t h a t in a l a r g e r sample<br>
s i z e , the reductions in Triglycerides and LDL and the<br>
increase in HDL, both d e s i r a b l e treatment effects,<br>
would be confirmed as s i g n i f i c a n t.<br>
[0062] It i s also clear from the r e g r e s s i o n analysis<br>
t h a t decreases in Blood Lipid values are a function of<br>
the Base l e v e l . These r e s u l t s suggest t h a t for those<br>
subjects in the population with highly elevated serum<br>
16<br>
cholesterol values, Nanocosanol™ has the p o t e n t i a l to<br>
bring about 15% -20% reductions.<br>
[0063] Many modifications and other embodiments of<br>
the invention will come t o the mind of one s k i l l e d in<br>
the art having the benefit of the teachings presented<br>
in the foregoing d e s c r i p t i o n s and the associated<br>
drawings. Therefore, i t is understood that the<br>
invention i s not to be limited to the specific<br>
embodiments disclosed, and that modifications and<br>
embodiments are intended to be included within the<br>
scope of the appended claims.<br>
T 17<br><br><br><br><br><br><br><br><br><br>
We claim:<br>
1. A method of supporting the maintenance of healthy blood lipid levels, reducing blood<br>
serum cholesterol levels and treating hypercholesterolemy in human and animal subjects<br>
by the oral administration of a human or animal dietary supplement composition<br>
comprising a blood lipid health-effective amount of one or more long chain (C24-C36)<br>
primary alcohols comprising policosanols dispersed in food-grade fats or oils, wherein<br>
the average particle sizes of the alcohols are greater than 2.0 microns, wherein the<br>
food-grade fats and oils comprise:<br>
not less than twenty five (25%) by weight of polyunsaturated fatty acids;<br>
not less than ten percent (10%) by weight of omega-3 fatty acids;<br>
not less than eight fifty parts per million (850 ppm) by weight of tocopherols and<br>
tocotrienols in total; and<br>
wherein the policonsanols comprise from about 0.1 percent by weight of the fats<br>
or oils to about 6.0 percent by weight of the fats and oils, and further<br>
comprising a food-grade emulsifier.<br>
2. The method as claimed in claim 1, wherein the composition is administered to the<br>
human or animal subjects in an amount to provide a daily intake of from about 0.125<br>
mg of the policosanols per kilogram of body weight per day to about 0.750 mg of the<br>
policosanols per kilogram of body weight per day and preferably in the range of about<br>
0.3 mg of policosanols per kilogram of body weight per day.<br>
3. The method as claimed in claim 1, wherein the average particle sizes of the alcohols are<br>
greater than 2.0 microns and less than 10.0 microns.<br>
4. The method as claimed in claim 1, wherein the alcohols comprise at least one of<br>
octacosanol, triacontanol and hexacosanoi.<br>
5. The method as claimed in claim 1, and further comprising forming the alcohols from<br>
natural sources comprising at least one of rice bran, beeswax, sugar cane, sorghum and<br>
wheat.<br>
18<br>
6. The method as claimed in claim 1, wherein the food-grade fats or oils further comprise:<br>
not less than two and one-half percent (2.5%) by weight of squalene.<br>
7. The method as claimed in claim 1, wherein the food-grade fats or oils comprise at least<br>
one of cranberry seed oil, amaranth seed oil, fish and marine/algal oils, safflower oil,<br>
sunflower seed oil, soybean oil, canola oil, olive oil, linseed oil, flax oil, hemp oil, borage<br>
oil, evening primrose oil, chia oil and hibiscus oil.<br>
8. The method as claimed in claim 1, wherein the pollcosanols comprise from about 0.5%<br>
by weight of the fats or oils to about 5.0% by weight of the fats or oils.<br>
9. The method as claimed in claim 1, wherein the pollcosanols comprise from about 1.0%<br>
by weight of the fats or oils to about 5.0% by weight of the fats or oils.<br>
10. The method as claimed in claim 1, further comprising adding biologically active extracts<br>
and compounds selected from at least one of minerals, carotenoids, tocopherols,<br>
tocotrienols, phytosterols, polyphenols, polysaccharides and bioflavonoids.<br>
11. The method as claimed in claim 1, further comprising forming a delivery vehicle as an<br>
emulsion, solution, dispersion, cream, tablet, capsules or powder.<br>
12. The method as claimed in claim 1, further comprising forming a delivery vehicle as a<br>
food, feed or beverage.<br>
13. A human or animal dietary supplement composition comprising a blood lipid healtheffective<br>
amount of one or more long chain (C24-C36) primary alcohols comprising<br>
pollcosanols, dispersed in food-grade fats or oils, wherein the average particle sizes of<br>
the alcohols are greater than 2.0 microns, wherein the food-grade fats or oils comprise:<br>
(a) not less than twenty five percent (25%) by weight of polyunsaturated<br>
fatty acids;<br>
(b) not less than ten percent (10%) by weight of omega-3 fatty acids;<br>
19<br>
(c) not less than eight fifty parts per million (850 ppm) by weight of<br>
tocopherols and tocotrlenols in total; and<br>
wherein the policosanols comprise from about 0.1 percent by weight of the fats<br>
or oils to about 6.0 percent by weight of the fats or oils, and further comprising a<br>
food-grade emulsifier.<br>
14. The composition as claimed in claim 13, wherein the average particle sizes of the<br>
alcohols are greater than 2.0 microns and less than 10.0 microns.<br>
15. The composition as claimed in claim 13, wherein the alcohols are selected from at least<br>
one of octacosanol, triacontanol and hexacosanol.<br>
16. The composition as claimed in claim 13, wherein the alcohols are selected from natural<br>
sources comprising at least one of rice bran, beeswax, sugar cane, sorghum and wheat.<br>
17. The composition as claimed in claim 13, wherein the food-grade fats or oils comprise at<br>
least one of cranberry seed oil, amaranth seed oil, fish and marine/algal oils, safflower<br>
oil, sunflower seed oil, soybean oil, canola oil, olive oil, linseed oil, flax oil, hemp oil,<br>
borage oil, evening primrose oil, chia oil and hibiscus oil.<br>
18. The composition as claimed in claim 13, wherein the policosanols comprise from about<br>
0.5% by weight of the fats or oils to about 5.0% by weight of the fats or oils.<br>
19. The composition as claimed in claim 13, wherein the policosanols comprise from about<br>
1.0% by weight of the fats or oils to about 5.0% by weight of the fats or oils.<br>
20. The composition as claimed in claim 13, and further comprising biologically active<br>
extracts and compounds, including at least one of carotenoids, phytosterols,<br>
polyphenols, polysaccharides and bioflavonoids.<br>
21. The composition as claimed in claim 13, and further comprising a delivery vehicle as an<br>
emulsion, solution, dispersion, cream, tablet, capsules or powder.<br>
20<br>
22. The composition as claimed in claim 13, and further comprising a delivery vehicle for<br>
carrying the composition comprising food, feed or beverage.<br>
23. The composition as claimed in claim 13, wherein the food-grade fats or oils contain<br>
squalene.<br>
24. The composition as claimed in claim 13, wherein the average particle sizes of the<br>
alcohols are less than 10 microns.<br>
25. A method for enhancing gastrointestinal motility in humans and other mammals,<br>
comprising administering a therapeutically effective amount of a composition having one<br>
or more long chain (C24-C36) primary alcohols as policosanols dispersed in one or more<br>
food-grade fats or oils, wherein the food-grade fats or oils comprise:<br>
(a) not less than twenty five percent (25%) by weight of polyunsaturated<br>
fatty acids;<br>
(b) not less than ten percent (10%) by weight of omega-3 fatty acids;<br>
(c) not less than eight fifty parts per million (850 ppm) by weight of<br>
tocopherols and tocotrienols in total; and<br>
wherein the policosanols comprise from about 0.1% by weight of the fats or oils<br>
to about 6.0% by weight of the fats or oils, and<br>
the particle sizes of the alcohols are greater than 2.0 microns.<br>
26. The method as claimed in claim 25, wherein the food-grade fats or oils further<br>
comprises not less than two and one-half percent (2.5%) by weight of squalene.<br>
27. The method as claimed in claim 25, wherein the alcohols are selected from natural<br>
sources including rice bran, beeswax, sugar cane, sorghum and wheat.<br>
28. The method as claimed in claim 25, wherein the food-grade fats or oils include at least<br>
one of cranberry seed oil, amaranth seed oil, fish and marine/algal oils, safflower oil,<br>
21<br>
sunflower seed oil, soybean oil, canola oil, olive oil, linseed oil, flax oil, hemp oil, borage<br>
oil, evening primrose oil, cha oil and hibiscus oil.<br>
29. The method as claimed in claim 25, wherein the policosanols comprise from about 0.5%<br>
by weight of the fats or oils to about 5.0% by weight of the fats or oils.<br>
30. The method as claimed in claim 25, wherein the policosanols comprise from about 1.0%<br>
by weight of the fats or oils to about 5.0% by weight of the fats or oils.<br>
31. The method as claimed in claim 25, the composition further comprising biologically<br>
active extracts and compounds, including vitamins, minerals, antioxidants, carotenoids,<br>
tocopherols, tocotrienols, phytosterols, polyphenols, polysaccharides and bioflavonoids.<br>
32. The method as claimed in claim 25, the composition further comprising a delivery<br>
vehicle as an emulsion, solution, dispersion, cream, tablet, capsules and powder.<br>
33. The method as claimed in claim 25, the composition further comprising a deliver vehicle<br>
for carrying the composition comprising food, feed or beverage.<br>
Dated this 31** day of July, 2008<br>
^ '<br>
(N^ti Wilson)<br>
Of Anand and Anand Advocates ^<br>
Attorney for the Applicant I<br>
!<br>
I<br>
22</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTcwMTMtUDJfUmVmaWxpbmcucGRm" target="_blank" style="word-wrap:break-word;">17013-P2_Refiling.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1ERUxOUC0yMDA4LUFzc2lnbm1lbnQgKDA3LTExLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">6669-DELNP-2008-Assignment (07-11-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUFzc2lnbm1lbnQtKDA5LTA3LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Assignment-(09-07-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNsYWltcy0oMTAtMDEtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Claims-(10-01-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNsYWltcy0oMTQtMTItMjAxMSkucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Claims-(14-12-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMDktMDctMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence Others-(09-07-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMTAtMDEtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence Others-(10-01-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1ERUxOUC0yMDA4LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMTAtMDktMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6669-DELNP-2008-Correspondence Others-(10-09-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMTEtMDUtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence Others-(11-05-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMjYtMTItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence Others-(26-12-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1ERUxOUC0yMDA4LUNvcnJlc3BvbmRlbmNlLW90aGVycyAoMDctMTEtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">6669-DELNP-2008-Correspondence-others (07-11-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1ERUxOUC0yMDA4LUNvcnJlc3BvbmRlbmNlLW90aGVycyAoMTgtMTItMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">6669-DELNP-2008-Correspondence-others (18-12-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDItMDktMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence-Others-(02-09-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDQtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence-Others-(04-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTMtMDgtMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence-Others-(13-08-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTQtMTItMjAxMSkucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Correspondence-Others-(14-12-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUZvcm0tMTMtKDE0LTEyLTIwMTEpLnBkZg==" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Form-13-(14-12-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1ERUxOUC0yMDA4LUZvcm0tMyAoMTgtMTItMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">6669-DELNP-2008-Form-3 (18-12-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LUZvcm0tMy0oMDQtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-Form-3-(04-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1ERUxOUC0yMDA4LUdQQSAoMDctMTEtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">6669-DELNP-2008-GPA (07-11-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LXBjdC0yMTAucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LXBjdC0yMjAucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-pct-220.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LXBjdC0yMzcucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-pct-237.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LXBjdC00MDEucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-pct-401.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LXBjdC00MDkucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-pct-409.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY2OS1kZWxucC0yMDA4LXBjdC00MTYucGRm" target="_blank" style="word-wrap:break-word;">6669-delnp-2008-pct-416.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=QUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Rm9ybSAyICBjb21wbGV0ZSBzcGVjaWZpY2F0aW9ucy5wZGY=" target="_blank" style="word-wrap:break-word;">Form 2  complete specifications.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=UkVWSVNFRCBDTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">REVISED CLAIMS.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="258528-an-electromagnetic-current-limiter-device.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="258530-a-liquid-filter-cartridge-for-use-inside-of-a-housing-of-a-liquid-filter-assembly.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>258529</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>6669/DELNP/2008</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>04/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>24-Jan-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>17-Jan-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>31-Jul-2008</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>U.S . NUTRACEUTICALS LLC DBA VALENSA INTERNATIONAL</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>2751 NUTRA LANE, EUSTIS, FLORIDA 32726 USA.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>EVANS DAVID A.</td>
											<td>933 HAMPTON COURT,EDMONTON, ALBERTA T6R 2S2 CANADA.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>HILL W. STEPHEN</td>
											<td>2751 NUTRA LANE, EUSTIS, FLORIDA 32726 USA.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A23L</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2007/003278</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2007-02-07</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/771,003</td>
									<td>2006-02-07</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>11/671,757</td>
									<td>2007-02-06</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/258529-dietary-supplement-composition-for-blood-lipid-health by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 05:16:59 GMT -->
</html>
